细胞遗传学异常对症状性多发性骨髓瘤的影响关西骨髓瘤论坛对日本现实世界的分析

IF 0.7 Q4 HEMATOLOGY Leukemia Research Reports Pub Date : 2023-01-01 DOI:10.1016/j.lrr.2023.100395
Aya Nakaya , Hirohiko Shibayama , Nobuhiko Uoshima , Ryosuke Yamamura , Satoshi Yoshioka , Kazunori Imada , Yuji Shimura , Masaaki Hotta , Toshimitsu Matsui , Satoru Kosugi , Hitoshi Hanamoto , Hitoji Uchiyama , Satoshi Yoshihara , Shin-ichi Fuchida , Yoshiyuki Onda , Yasuhiro Tanaka , Kensuke Ohta , Mitsuhiro Matsuda , Junya Kanda , Adachi Yoko , Masayuki Hino
{"title":"细胞遗传学异常对症状性多发性骨髓瘤的影响关西骨髓瘤论坛对日本现实世界的分析","authors":"Aya Nakaya ,&nbsp;Hirohiko Shibayama ,&nbsp;Nobuhiko Uoshima ,&nbsp;Ryosuke Yamamura ,&nbsp;Satoshi Yoshioka ,&nbsp;Kazunori Imada ,&nbsp;Yuji Shimura ,&nbsp;Masaaki Hotta ,&nbsp;Toshimitsu Matsui ,&nbsp;Satoru Kosugi ,&nbsp;Hitoshi Hanamoto ,&nbsp;Hitoji Uchiyama ,&nbsp;Satoshi Yoshihara ,&nbsp;Shin-ichi Fuchida ,&nbsp;Yoshiyuki Onda ,&nbsp;Yasuhiro Tanaka ,&nbsp;Kensuke Ohta ,&nbsp;Mitsuhiro Matsuda ,&nbsp;Junya Kanda ,&nbsp;Adachi Yoko ,&nbsp;Masayuki Hino","doi":"10.1016/j.lrr.2023.100395","DOIUrl":null,"url":null,"abstract":"<div><p>To evaluate the specific prognostic value of CAs, we conducted an analysis of 923 symptomatic multiple myeloma patients. Among this cohort, 480 patients had complete data set of high-risk CAs by interphase fluorescent in situ hybridization at diagnosis. In the high-risk group analysis, the median OS of patients without CAs (<em>n</em> = 338, 72 %) was 6.5 years, patients with del(17p) (<em>n</em> = 42, 9 %) was 4.4 years, patients with t(4;14) or t(14;16) (<em>n</em> = 72, 15 %) was 4.4 years, and patients with double-positive CAs(del(17p) and t(4;14) or t(14;16)) (<em>n</em> = 18, 4 %) was 2.1 years (<em>p</em> = 0.032). Patients with double-positive CAs had a significantly worse prognosis.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048923000353/pdfft?md5=da41e0ae4551170b1083dfbc3d685562&pid=1-s2.0-S2213048923000353-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum\",\"authors\":\"Aya Nakaya ,&nbsp;Hirohiko Shibayama ,&nbsp;Nobuhiko Uoshima ,&nbsp;Ryosuke Yamamura ,&nbsp;Satoshi Yoshioka ,&nbsp;Kazunori Imada ,&nbsp;Yuji Shimura ,&nbsp;Masaaki Hotta ,&nbsp;Toshimitsu Matsui ,&nbsp;Satoru Kosugi ,&nbsp;Hitoshi Hanamoto ,&nbsp;Hitoji Uchiyama ,&nbsp;Satoshi Yoshihara ,&nbsp;Shin-ichi Fuchida ,&nbsp;Yoshiyuki Onda ,&nbsp;Yasuhiro Tanaka ,&nbsp;Kensuke Ohta ,&nbsp;Mitsuhiro Matsuda ,&nbsp;Junya Kanda ,&nbsp;Adachi Yoko ,&nbsp;Masayuki Hino\",\"doi\":\"10.1016/j.lrr.2023.100395\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>To evaluate the specific prognostic value of CAs, we conducted an analysis of 923 symptomatic multiple myeloma patients. Among this cohort, 480 patients had complete data set of high-risk CAs by interphase fluorescent in situ hybridization at diagnosis. In the high-risk group analysis, the median OS of patients without CAs (<em>n</em> = 338, 72 %) was 6.5 years, patients with del(17p) (<em>n</em> = 42, 9 %) was 4.4 years, patients with t(4;14) or t(14;16) (<em>n</em> = 72, 15 %) was 4.4 years, and patients with double-positive CAs(del(17p) and t(4;14) or t(14;16)) (<em>n</em> = 18, 4 %) was 2.1 years (<em>p</em> = 0.032). Patients with double-positive CAs had a significantly worse prognosis.</p></div>\",\"PeriodicalId\":38435,\"journal\":{\"name\":\"Leukemia Research Reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2213048923000353/pdfft?md5=da41e0ae4551170b1083dfbc3d685562&pid=1-s2.0-S2213048923000353-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Leukemia Research Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213048923000353\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213048923000353","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

为了评估ca的具体预后价值,我们对923例有症状的多发性骨髓瘤患者进行了分析。在该队列中,480例患者在诊断时通过间期荧光原位杂交具有完整的高危CAs数据集。在高危组分析中,无ca患者(n = 338, 72%)的中位OS为6.5年,del(17p)患者(n = 42,9 %)为4.4年,t(4;14)或t(14;16)患者(n = 72,15 %)为4.4年,双阳性ca (del(17p)和t(4;14)或t(14;16)患者(n = 18,4 %)为2.1年(p = 0.032)。双阳性ca患者预后明显较差。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum

To evaluate the specific prognostic value of CAs, we conducted an analysis of 923 symptomatic multiple myeloma patients. Among this cohort, 480 patients had complete data set of high-risk CAs by interphase fluorescent in situ hybridization at diagnosis. In the high-risk group analysis, the median OS of patients without CAs (n = 338, 72 %) was 6.5 years, patients with del(17p) (n = 42, 9 %) was 4.4 years, patients with t(4;14) or t(14;16) (n = 72, 15 %) was 4.4 years, and patients with double-positive CAs(del(17p) and t(4;14) or t(14;16)) (n = 18, 4 %) was 2.1 years (p = 0.032). Patients with double-positive CAs had a significantly worse prognosis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Leukemia Research Reports
Leukemia Research Reports Medicine-Oncology
CiteScore
1.70
自引率
0.00%
发文量
70
审稿时长
23 weeks
期刊最新文献
Late-onset Familial Hemophagocytic Lymphohistiocytosis in a survivor of Hodgkin's Lymphoma Posterior reversible encephalopathy syndrome (PRES) and myeloma IDH2-mutated near ETP-ALL with aggressive leukemia cutis and brisk response to venetoclax and decitabine Genomic heterogeneity within B/T mixed phenotype acute leukemia in a context of an immunophenotype Avapritinib treatment of aggressive systemic mastocytosis with a novel KIT exon 17 mutation
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1